With the approval of the single-dose J&J vaccine, India has five vaccines that have got approval for emergency use. The others are Covishield, Covaxin, Sputnik V and Moderna.
Johnson & Johnson Friday said that it remains committed to bringing the single-dose vaccine and accelerating its availability in India through collaboration with Biological E.
The study, released on bioRxiv, found that J&J’s shot produced roughly five-fold lower levels of antibodies against Delta strain compared to levels raised against an early strain.
J&J said the recipients of its vaccine produced strong neutralising antibodies over the course of at least eight months against all variants, including Delta.
This comes after the US Supreme Court refused to consider J&J’s objections to a 2018 jury finding. The company still faces more than 25,000 lawsuits blaming baby powder for causing cancers.
In late March, workers at a biodefence plant in Baltimore accidentally mixed ingredients of Johnson & Johnson and AstraZeneca vaccines, contaminating 15 million doses.
More than than 8 million Americans have been given J&J’s vaccine, which was haulted after a number of cases of blood clots emerged, especially in young women.
Like China, India remains a big domestic market, which will continue to attract investment, but the US tariffs will make India unattractive for future investments.
New bill aims to fix key issues with IBC 2016, including delays & patchy implementation, and protect creditors, with window for genuine promoters to retain control of their companies.
Contrary to claims regarding implementation of theaterisation, ThePrint first reported on 17 June 2021 that it will be delayed. Now, ACM Singh bats for different structure.
Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.
COMMENTS